1-20 of 25
european system for cardiac operative risk evaluation
Close
Sort by
Journal Articles

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Susanne Beck, Martina Emde, Jerome Moreaux, PhD, Anja Seckinger, Dirk Hose, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3078.
https://doi.org/10.1182/blood-2019-131161
Published: 2019
Journal Articles

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Luis Felipe Casado Montero, Valentin Garcia Gutierrez, MD, Pilar Giraldo, MD PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, MD PhD, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3074.
https://doi.org/10.1182/blood.V128.22.3074.3074
Published: 2016
Journal Articles

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Franck E. Nicolini, MD PhD, Gaelle Fossard, MD, Valerie Coiteux, MD, Viviane Dubruille, MD, Vincent Alcazer, MD, Mohamad Sobh, PharmD, Pierre Mouchel, MD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD, Agnes Guerci, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1894.
https://doi.org/10.1182/blood.V128.22.1894.1894
Published: 2016
Journal Articles

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Susanne Saussele, Mareike Stein, Arthur Gil, Ute Kossak-Roth, Michael Lauseker, PhD, Ulrike Proetel, Hermann Einsele, MD, Philippe Schafhausen, Elisabeth Lange, Mathias Hänel, Karsten Spiekermann, MD, Martin Sökler, MD, Clemens Wendtner, Stephan Kremers, Michael Pfreundschuh, Ernst Holler, Wolf-Karsten Hofmann, Andreas Hochhaus, MD, Martin C. Müller, Ruediger Hehlmann, MD, Markus Pfirrmann
Journal: Blood
Blood (2015) 126 (23): 2773.
https://doi.org/10.1182/blood.V126.23.2773.2773
Published: 2015
Journal Articles

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Verena Sophia Hoffmann, Dr., Michele Baccarani, Joerg Hasford, MD, Doris Lindoerfer, Sonja Burgstaller, MD, Dubravka Sertic, MD, Paul Costeas, Jiri Mayer, Karel Indrak, MD, Hele Everaus, MD PhD, Perttu Koskenvesa, Joelle Guilhot, PhD, Gabriele Schubert-Fritschle, Fausto Castagnetti, MDPhD, Francesco Di Raimondo, MDPhD, Sandra Lejniece, PhD MD, Laimonas Griskevicius, Noortje Thielen, MDPhD, Thomas Sacha, Andrzej Hellmann, MD PhD, Anna Turkina, Prof., MD, Andrey Zaritskey, MD, Andrija Bogdanovic, MD PhD MSc,, Zuzana Sninska, Irena Zupan, Felipe Casado, Bengt Simonsson, MD, Richard E. Clark, MD, Susanne Saussele, Andreas Hochhaus, MD, Ruediger Hehlmann, MD
Journal: Blood
Blood (2015) 126 (23): 2780.
https://doi.org/10.1182/blood.V126.23.2780.2780
Published: 2015
Journal Articles

Systematic Review and Meta-Analysis of Randomized Trials Comparing Imatinib 400 Mg/d Vs. Imatinib 800 Mg/d, and Imatinib 400 Mg/d Vs. Second Generation TKIs in Chronic Phase CML-Patients

Verena Sophia Hoffmann, Dr., Joerg Hasford, MD, Ruediger Hehlmann, MD
Journal: Blood
Blood (2015) 126 (23): 2787.
https://doi.org/10.1182/blood.V126.23.2787.2787
Published: 2015
Journal Articles

EUTOS Score Predicts Long-Term Outcome in Chronic Myeloid Leukemia Patients Transitioning from Pre-Imatinib Era to Imatinib upon Availability

Pratik Deb, MBBS, Uttam Nath, M.B.B.S., MD, D.M., Rajarshi Aich, M.B.B.S, Siddhartha Sankar Ray, M.B.B.S., MD, D.M., Prantar Chakrabarti, MBBS,MDDM
Journal: Blood
Blood (2015) 126 (23): 4023.
https://doi.org/10.1182/blood.V126.23.4023.4023
Published: 2015
Journal Articles

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Christian T. Dietz, PhD, Alice Charlotte Fabarius, PhD, Michael Lauseker, PhD, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Professor, Nicolaus Kröger, Dietrich W. Beelen, MD, Jürgen Novotny, Christoph Nerl, Christof Scheid, MD PhD, Karsten Spiekermann, Jiri Mayer, MD, Herbert G. Sayer, Christiane Falge, Donald Bunjes, MD, Hartmut Döhner, Prof. Dr., Arnold Ganser, Peter Brossart, MD, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, MD, Matthias Bormann, Bernd Hertenstein, MD, Gabriela M. Baerlocher, Carlo Aul, MD, Peter Staib, Matthias Edinger, MD, Michael Schatz, Axel A Fauser, Renate Arnold, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, Susanne Schnittger, PhD, Martin C. Müller, MD, Andreas Reiter, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann, MD
Journal: Blood
Blood (2015) 126 (23): 1581.
https://doi.org/10.1182/blood.V126.23.1581.1581
Published: 2015
Journal Articles

Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia

Markus Pfirrmann, PhD, Susanne Saussele, MD PhD, Michele Baccarani, MD PhD, Joelle Guilhot, PhD, Francisco Cervantes, MD PhD, Gert J Ossenkoppele, MDPhD, Doris Lindoerfer, Verena S Hoffmann, Dr., Fausto Castagnetti, MD PhD, Rüdiger Hehlmann, MD, Bengt Simonsson, MD PhD
Journal: Blood
Blood (2014) 124 (21): 153.
https://doi.org/10.1182/blood.V124.21.153.153
Published: 2014
Journal Articles

Safety and Efficacy Of Imatinib In Elderly Patients With Chronic-Phase Chronic Myeloid Leukemia: Analysis Of Outcome For < 60 Years Versus ≥ 60 Years

Young-Woong Won, M.D., Ph.D., DongWook Kim, Sung-Eun Lee, M.D., Soo Young Choi, Soo-Hyun Kim, Eun-Jung Jang
Journal: Blood
Blood (2013) 122 (21): 4039.
https://doi.org/10.1182/blood.V122.21.4039.4039
Published: 2013
Journal Articles

Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only

Markus Pfirrmann, PhD, Susanne Saussele, MD, Michele Baccarani, MD, Joelle Guilhot, PhD, Francisco Cervantes, MD, PhD, Gert J. Ossenkoppele, MD PhD, Doris Lindörfer, MSc, Verena S Hoffmann, PhD, Fausto Castagnetti, Rüdiger Hehlmann, MD, Bengt Simonsson, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 382.
https://doi.org/10.1182/blood.V122.21.382.382
Published: 2013
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Luis Felipe Casado, MD, PhD, Begoña Maestro, J. Valentin García-Gutiérrez, Marie Hélène Dumas, Isabel Massague, Pilar Giraldo, MD, PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquín Martínez-López, MD, Guiomar Bautista, MD, Santiago Osorio, Maria José Requena, Luis Palomera, MD, Maria Jesús Peñarrubia, Carmen Calle, Jose Ángel Hernández-Rivas, Carmen Burgaleta, Marcio M Andrade, Sr., MD, Nuria García-Ormena, Juan Luis Steegmann, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3762.
https://doi.org/10.1182/blood.V120.21.3762.3762
Published: 2012
Journal Articles

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Rüdiger Hehlmann, MD, Michael Lauseker, Benjamin Hanfstein, MD, Martin C. Müller, MD, Annette Schreiber, MD, Ulrike Proetel, MD, Markus Pfirrmann, Claudia Haferlach, MD, Susanne Schnittger, PhD, Hermann Einsele, Jolanta Dengler, MD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, PhD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Karsten Spiekermann, MD, Gabriela M. Baerlocher, MD, Gerhard Ehninger, Dominik Heim, MD, Hermann Heimpel, Christoph Nerl, MD, Stefan W. Krause, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, MD, Andreas Hochhaus, MD, Joerg Hasford, Susanne Saussele, MD
Journal: Blood
Blood (2012) 120 (21): 67.
https://doi.org/10.1182/blood.V120.21.67.67
Published: 2012
Journal Articles

Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV,

Susanne Saussele, MD, Michael Lauseker, Verena Hoffmann, MA., Ulrike Proetel, MD, Benjamin Hanfstein, MD, Gabriela M. Baerlocher, MD, Dominik Heim, MD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, PhD, Hans-Jochem Kolb, MD, Stefan W. Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Joerg E. A. Schubert, MD, Hermann Einsele, MD, Matthias Hänel, MD, Anthony D. Ho, MD, PhD, Christiane Falge, MD, Lothar Kanz, MD, Andreas Neubauer, MD, Michael Kneba, MD, Frank Stegelmann, MD, Michael Pfreundschuh, MD, Cornelius F. Waller, MD, Karsten Spiekermann, MD, Susanne Schnittger, PhD, Markus Pfirrmann, PhD, Andreas Hochhaus, MD, Jörg Hasford, MD, Rüdiger Hehlmann, MD, Martin C Müller, MD, for The SAKK, The German CML Study Group
Journal: Blood
Blood (2011) 118 (21): 3762.
https://doi.org/10.1182/blood.V118.21.3762.3762
Published: 2011
Journal Articles

Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months

Michele Baccarani, Gianantonio Rosti, Giovanni Martinelli, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Nicoletta Testoni
Journal: Blood
Blood (2010) 116 (21): 668.
https://doi.org/10.1182/blood.V116.21.668.668
Published: 2010
Journal Articles

Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV.

Susanne Saussele, MD, Nadine Pletsch, MD, Michael Lauseker, Armin Leitner, MD, Susanne Jung-Munkwitz, MD, Ulrike Proetel, MD, Martin C. Müller, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, PhD, Gerhard Ehninger, MD, Dieter K. Hossfeld, MD, Stefan W. Krause, MD, Christoph Nerl, MD, PhD, Hans Pralle, MD, Dominik Heim, MD, Gabriela M. Baerlocher, MD, Leopold Balleisen, MD, Hermann Einsele, MD, Anthony D. Ho, MD, FRCPC, Christiane Falge, MD, Matthias Hänel, MD, M. Pfreundschuh, Lothar Kanz, MD, Frank Stegelmann, MD, Claus-Henning Köhne, MD, Stephan Kremers, MD, Karsten Spiekermann, MD, Steffen Koschmieder, MD, Cornelius F. Waller, MD, Martin Bentz, MD, Markus Pfirrmann, PhD, Andreas Hochhaus, Jörg Hasford, MD, Rüdiger Hehlmann, MD, for The German CML-Study Group
Journal: Blood
Blood (2010) 116 (21): 3411.
https://doi.org/10.1182/blood.V116.21.3411.3411
Published: 2010
Journal Articles

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Rudiger Hehlmann, Susanne Jung-Munkwitz, Michael Lauseker, Armin Leitner, Nadine Pletsch, Samina Shazi, Martin C. Müller, Claudia Haferlach, Brigitte Schlegelberger, Susanne Schnittger, PhD, Cornelius F. Waller, Andreas Neubauer, Lothar Kanz, MD, Mathias Hänel, Jiri Mayer, Frank Stegelmann, Roland Fuchs, Wolfgang E. Berdel, Leopold Balleisen, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans- Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Joerg Hasford, Andreas Hochhaus, Susanne Saussele, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 339.
https://doi.org/10.1182/blood.V114.22.339.339
Published: 2009
Journal Articles

Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV.

Susanne Saussele, Michael Lauseker, Markus Pfirrmann, Armin Leitner, Nadine Pletsch, Frank Stegelmann, Anthony D Ho, Günter Schlimok, Albrecht Lindemann, Dietrich W Beelen, Alois Gratwohl, Mathias Hänel, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Philipp Erben, Susanne Schnittger, Susanne Jung-Munkwitz, Samina Shazi, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 3287.
https://doi.org/10.1182/blood.V114.22.3287.3287
Published: 2009
Journal Articles

Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS.

Joerg Hasford, MD, Gianantonio Rosti, MD, Doris Lindoerfer, Dipl.-Inf., Michele Baccarani, MD, Joelle Guilhot, MSci, Lara Montrucchio, Francesca Rancati, PhD, Bengt Simonsson, MD, Franck Emmanuel Nicolini, MD, PhD, Gert Ossenkoppele, MD, Ruediger Hehlmann, MD
Journal: Blood
Blood (2009) 114 (22): 1109.
https://doi.org/10.1182/blood.V114.22.1109.1109
Published: 2009